CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Awards and Warrants - Private Placement of Shares of Common Stock and Warrants (Details)

Equity Awards and Warrants - Private Placement of Shares of Common Stock and Warrants (Details) - USD ($)	1 Months Ended		3 Months Ended			6 Months Ended
	Aug. 31, 2023	Jul. 31, 2023	Nov. 30, 2023	Sep. 30, 2023	Aug. 31, 2022	Nov. 30, 2023	Nov. 30, 2022	Oct. 23, 2023	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of share		$ 0.306		$ 0.50					$ 0.306	$ 0.50
Exercise of warrants for cash, shares						3,000,000.0
Exercise of warrants for cash						$ 300,000
Common stock warrants to purchase shares				21,500,000
Purchase price per unit								$ 0.16
Cash and non-cash issuance costs capitalized		$ 900,000
Loss on extinguishment of convertible notes		2.4	$ (2,406,000)			(4,490,000)
Term of warrants				5 years
Placement agent fees and expenses				$ 400,000
Percentage of gross proceeds				12.00%
Stock issued for private offerings			$ 6,328,000
Issuance of common stock for principal of convertible notes						$ 2,000,000	$ 500,000
Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued during the period new issues shares						153,027	460,095
Share-Based Payment Arrangement, Grantee Status [Extensible Enumeration]						Share-based Payment Arrangement, Nonemployee [Member]	Share-based Payment Arrangement, Nonemployee [Member]
Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stocks issued for severance payment						1,091,865	510,872
Share-Based Payment Arrangement, Grantee Status [Extensible Enumeration]						Share-based Payment Arrangement, Nonemployee [Member]	Share-based Payment Arrangement, Nonemployee [Member]
Placement agent notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Loss on extinguishment of convertible notes		(2,100,000)
Private Equity Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued for private offerings					$ 17,544,000
Accredited Investors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock warrants to purchase shares				21,500,000
Stock issued for private offerings				$ 3,000,000.0
Accredited Investors \| Placement agent notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock for principal of convertible notes		$ 2,300,000
Warrants issued in debt conversion		14,300,000
Allotment to placement agent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of share				$ 0.16
Common stock warrants to purchase shares				3,200,000
Term of warrants				10 years
Placement agent fees and expenses	$ 5,000,000	$ 5,000,000
Percentage of gross proceeds				15.00%
July Private Placement \| Placement agent notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price per unit		$ 0.16
Number of common shares in a fixed combination issue of shares		1
Number of warrants in a fixed combination issue of securities		1
Number of shares		1
Closing share price (as percentage)		90.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of share			$ 0.10			$ 0.10